Filing Flows › NovoCure (NVCR) › Q3 2026
NovoCure (NVCR) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
NovoCure (NVCR) reported revenue of $193M for the third quarter 2026 (Q3 2026), +16% from a year earlier and +5% from the quarter before. Operating margin was -3.2%, net loss $10.4M (5.4% of revenue).
NovoCure, Q3 2026: revenue $193M (+16% year over year), operating margin -3.2%, net loss $10.4M, operating cash flow $22.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $193M | +5% | +16% |
| Operating profit | −$6.2M | — | — |
| Net earnings | −$10.4M | — | — |
| Operating cash flow | $22.7M | +179% | +10% |
| Free cash flow | $15.7M | 13× | +6% |
What changed
Revenue was $193.4M in Q3 2026, up 16% year over year and up 5% from the previous quarter.
Gross margin was 77.0%, up 3.7 points from Q3 2025. Operating costs exceeded revenue by $6.2M, an operating margin of -3.2%. Operating expenses fell 2% while revenue rose 16%. The quarter ended with a net loss of $10.4M, narrower than the previous quarter's $15.7M loss.
Operating cash flow was $22.7M (up 10% year over year). Non-cash charges added back $4.4M of depreciation and amortization and $17.5M of share-based compensation. Working capital and other items added $11.2M. Capital expenditures of $6.9M left free cash flow of $15.7M.
Questions
What was NovoCure's revenue in the third quarter 2026?
NovoCure (NVCR) reported revenue of $193M for the third quarter 2026 (Q3 2026), +16% from a year earlier and +5% from the quarter before.
Was NovoCure profitable in the third quarter 2026?
Operating loss was $6.2M (-3.2% of revenue) and net loss $10.4M.
Source: NovoCure 10-Q on SEC EDGAR.